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BORIS (for brother of the regulator of imprinted sites), a paralogue of the transcription factor, CTCF, is a novel member of the
cancer-testis antigen family. The aims of the present study were as follows: (1) to investigate BORIS expression in breast cells and
tumours using immunohistochemical staining, western and real-time RT–PCR analyses and (2) assess potential correlation between
BORIS levels in tumours with clinical/pathological parameters. BORIS was detected in all 18 inspected breast cell lines, but not in a
primary normal breast cell culture. In 70.7% (41 of 58 cases) BORIS was observed in breast tumours. High levels of BORIS correlated
with high levels of progesterone receptor (PR) and oestrogen receptor (ER). The link between BORIS and PR/ER was further
confirmed by the ability of BORIS to activate the promoters of the PR and ER genes in the reporter assays. Detection of BORIS in a
high proportion of breast cancer patients implies potential practical applications of BORIS as a molecular biomarker of breast cancer.
This may be important for diagnosis of the condition and for the therapeutic use of BORIS. The ability of BORIS to activate
promoters of the RP and ER genes points towards possible involvement of BORIS in the establishment, progression and maintenance
of breast tumours.
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BORIS (for brother of the regulator of imprinted sites) is a
paralogue of the 11 zinc-finger transcription factor, CTCF. The
zinc-finger domain of BORIS protein has striking homology to
the CTCF zinc-finger domain; however, the N- and C-terminal
domains of BORIS are different from these domains of CTCF
(Klenova et al, 2002; Loukinov et al, 2002). BORIS is normally
expressed only in spermatocytes in the testis; however, it is
aberrantly expressed in various tumours and cancer cell lines
(Klenova et al, 2002; Loukinov et al, 2002; Hoffmann et al,
2006; Risinger et al, 2007). Interestingly, BORIS was found
in the leukocyte fraction of patients with breast cancer (D’Arcy
et al, 2006).
BORIS can be classified as a protein belonging to the cancer
testis antigen (CTA) family (Scanlan et al, 2004). The CTA gene
products exhibit highly tissue-restricted expression and are
immunogenic in cancer patients (Scanlan et al, 2002, 2004). The
CTAs have been grouped into 44 families and include up to 89 CTA
genes or isoforms, with most of their expression profiles studied in
numerous cancer types (Scanlan et al, 2004). The function of the
majority of the CTAs is still unknown; however, some CTAs are
thought to be implicated in the regulation of gene expression and
others may control gametogenesis (Old, 2001; Kalejs and
Erenpreisa, 2005). The CTAs are attractive targets for developing
cancer-specific immunotherapy because of their highly restricted
expression in normal tissues and broad expression in a wide range
of tumours (Chitale et al, 2005).
The human BORIS gene maps to chromosome 20q13.2
(Loukinov et al, 2002). This chromosome region is often amplified
in many cancers and is believed to contain a dominant
immortalising or transforming gene(s) (Tanner et al, 1994; Cuthill
et al, 1999). Recent reports show that BORIS is a downstream
regulator of cancer–testis genes: expression of BORIS in normal
cells leads to derepression of cancer–testis genes MAGE-A1,
NY-ESO-1 and others (Hong et al, 2005; Vatolin et al, 2005).
CTCF and BORIS are expressed in a mutually exclusive manner
during male germ-line development (Klenova et al, 2002; Loukinov
et al, 2002); thus, suggesting that BORIS may be important for
epigenetic reprogramming occurring during development in these
cells. Indeed, BORIS has been implicated in the initiation of a
series of methylation events at the imprinting control regions, in
the vicinity of the CTCF-/BORIS-binding sites (Jelinic et al, 2006),
which may be significant for cancer development (Jelinic and
Shaw, 2007).
As BORIS is not normally expressed in females, we asked
whether BORIS would be present in breast tumours and if so,
whether it would have characteristics of a cancer biomarker. In
this study, we demonstrate that BORIS protein indeed appears in
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sall breast cancer cell lines tested and in 70.7% of breast tumours.
We also identified positive correlations between the levels of
BORIS and progesterone receptor (PR) and oestrogen receptor
(ER) in breast tumours.
MATERIALS AND METHODS
Patients and controls
Primary human tumour breast tissues together with paired normal
peripheral tissues were collected during surgery from patients
treated at Colchester General Hospital (Essex, UK), with written
consent taken before surgery. The study was approved by the Local
Ethics Committee (reference number LREC MH363). Normal
breast tissue samples were collected after reduction surgery. Tissue
specimens were visually examined by an experienced pathologist
as fresh material, tumour tissues were selected by conventional
pathological criteria and the histopathology was further confirmed
by microscopic examination. The paired normal peripheral tissues
were removed during macroscopic examination of the tumour
by the pathologist. The samples were immediately frozen and
stored at –801C. Histology of the tissues is described in Table 1.
The following patient information was provided: tumour stage,
tumour grade, tumour size, ER status, PR status, HER-2 receptor
status, lymph node metastasis, preoperative and post-operative
chemotherapy, menopausal state and patient’s age.
Procedures
Cell lines A panel of 18 breast cell lines of different origins
composed of non-malignant and malignant human breast cells was
obtained from M O’Hare and B Gusterson. The two non-malignant
cell lines were HBL100 (Gaffney, 1982) and HB4a. The HB4a cells
were established from normal breast luminal cells immortalised
with SV40 T-antigen (Stamps et al, 1994). Malignant breast cell
lines included six ER-positive (ERþ) cells originating from
human breast carcinomas (T47D, MCF7, BT474, CAMA1, ZR75-1
and ZR75-30). Ten ER-negative breast cancer cell lines (ER )
contained HMT3522 (a cell line derived from fibrocystic breast
tissue); adherent carcinomas MDA-MB-175, MDA-MB-157, MDA-
MB-231, MDA-MB-435, MDA-MB-453, MDA-MB-468, SKBR5 and
SKBR7; and non-adherent carcinoma DU4475. All breast cancer
cell lines were maintained in RPMI-1640 medium supplemented
with HEPES, GlutaMAX and sodium bicarbonate, 50mgml
 1
gentamicin, 10% fetal calf serum (all from Life Technologies,
Paisley, UK). The HB4a cells were maintained in the same medium
with the addition of 5mgml
 1 of insulin and 5mgml
 1 of
hydrocortisone (both from Sigma, Poole, UK). Breast cell lines
Table 1 Assessment of the breast tissues for BORIS using immunohisto-
chemical staining with the anti-BORIS antibody
No Diagnosis
Percentage of positive
cells (group)
Staining
intensity
IRS
tissues
BR1 NBr 0 0 0
BR2 NBr 0 0 0
BR3 NBr 0 0 0
BR4 NBr 0 0 0
PP3 PP 0 0 0
PP6 PP o1 o1 o1
PP9 PP 0 0 0
PP11 PP 0 0 0
PP17 PP 0 0 0
PP19 PP 0 0 0
PP23 PP 0 0 0
PP28 PP 0 0 0
PP30 PP 0 0 0
Table 1 (Continued)
No Diagnosis
Percentage of positive
cells (group)
Staining
intensity
IRS
tissues
PP33 PP 0 0 0
PP42 PP 0 0 0
PP58 PP 0 0 0
PP71 PP 0 0 0
PP83 PP 0 0 0
PP89 PP 0 0 0
52 DCIS 2 2 4
58 DCIS 2 1 2
168 DCIS 1 1 1
279 DCIS 1 3 3
445 DCIS 0 0 0
2 IAC 0 0 0
3 IAC 0 0 0
19 IAC 0 0 0
28 IAC 0 0 0
71 IAC 1 1 1
89 IAC 2 3 6
144 IAC 2 1 2
210 IAC 2 1 2
6 IDC 1 2 2
11 IDC 1 1 1
15 IDC 0 0 0
16 IDC 0 0 0
17 IDC 1 2 2
23 IDC 0 0 0
30 IDC 1 1 1
41 IDC 1 1 1
51 IDC 0 0 0
73 IDC 2 2 4
83 IDC 2 1 2
135 IDC 0 0 0
138 IDC 0 0 0
192 IDC 2 1 2
195 IDC 3 2 6
197 IDC 3 1 3
209 IDC 3 2 6
214 IDC 3 2 6
222 IDC 2 2 4
228 IDC 3 2 6
229 IDC 2 1 2
251 IDC 3 3 9
258 IDC 0 0 0
281 IDC 3 2 6
290 IDC 2 2 4
292 IDC 4 2 8
309 IDC 2 1 2
326 IDC 2 2 4
328 IDC 2 2 4
352 IDC 0 0 0
393 IDC 0 0 0
428 IDC 3 2 6
453 IDC 3 1 3
265 ILC 1 2 2
332 ILC 2 1 2
333 ILC 2 2 4
357 ILC 0 0 0
413 ILC 3 1 3
417 ILC 2 1 2
446 ILC 2 2 4
9 MIXED 0 0 0
324 MIXED 4 2 8
440 MIXED 0 0 0
33 MUC CA 2 2 4
329 MUC CA 3 1 3
BR¼breast reduction tissues; NBr¼normal breast reduction tissues; PP¼paired
peripheral breast tissues; DCIS¼ductal carcinoma in situ;I A C¼invasive adenocarcinoma;
IDC¼invasive ductal carcinoma; ILC¼invasive lobular carcinoma; MIXED¼tumours
with mixed phenotypes; MUC CA¼mucinous carcinoma. Staining was assessed by the
immunoreactivity score (IRS) as described under the Materials and Methods section.
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kidney cells, 293T, were maintained in DMEM supplemented with
10% fetal calf serum and 50mgml
 1 gentamicin.
Expression vectors and transient transfections
The BORIS expression vector (pCMV6–BORIS) used in transient
transfections was described previously (Loukinov et al, 2002). The
pGL2-hPR (or pPRLuc) reporter construct was a kind gift from I
De Vivo. It contains the 1536-bp fragment ( 711 to þ825) of the
promoter of the PR gene fused with the luciferase reporter gene in
pGL2-basic plasmid (De Vivo et al, 2002; Huggins et al, 2006). The
pER3500-230L (or pERLuc) reporter construct was a kind gift from
RJ Weigel. It contains the 3730-bp fragment ( 3500 to þ230) of
the promoter of the ER gene fused with the luciferase reporter
gene in pGL2-basic plasmid (deConinck et al, 1995). Transient
transfections were performed using a calcium phosphate transfec-
tion protocol (Chen and Okayama, 1987).
Luciferase assay
Following transfection, cells were harvested and assayed using the
Luciferase Assay System according to the manufacturer’s instruc-
tions (Promega, Southampton, UK). Luminescence was measured
using a Labsystems Luminoskan luminometer (Life Sciences,
Runcorn, UK). To normalise for cell number and transfection
efficiency, 0.25mg b-galactosidase marker gene plasmid (pCH110)
was included per well in the transfection solution. Mean and s.d.
were calculated from the results of three experiments performed in
triplicate.
Primary breast cell culture
To obtain primary cells from fresh normal tissues, we essentially
used a method described earlier (Clarke et al, 1994) with
modifications. In brief, tissues were cut into small pieces
(1mm
3) and incubated for 2h on a rotating wheel at 371C in the
presence of 2.5mgml
 1 of collagenase type I from Clostridium
histolyticum (Sigma). After filtration through a 100-mm sieve
(Falcon, Fisher Scientific, Loughborough, UK), the suspension was
centrifuged at 1000g for 10min. Pellets were re-suspended in fresh
Leibovitz medium and centrifuged at 1000g for 10min. The
resulting pellet was washed three times with the filter-sterilised
washing buffer (1mM EDTA, 1% BSA in PBS). The final cell pellet
was re-suspended in 5ml of MEBM (mammary epithelium basal
medium) (Cambrex, now Lonza, Wokingham, UK), subsequently
filtered through a 100-mm and then a 40-mm sieve (Falcon,
Fisher Scientific, Loughborough, UK); after that cells were plated
in MEBM without sodium bicarbonate supplemented with the
MEGM SingleQuots (Cambrex) and fungizone, amphotericin B
(0.25mgml
 1) (all from Gibco, Invitrogen, Paisley, UK).
RNA isolation, reverse transcription and real-time PCR
analysis
Total RNA was isolated from tissues using a TRIZOL Reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instruction. The isolated RNA was quality tested using the Agilent
Bioanalyzer 2100. RNA was then converted to cDNA using random
primers and Thermoscript reverse transcriptase (Invitrogen). Real-
time RT–PCR analysis was performed as described previously
(Vatolin et al, 2005) using the Applied Biosystems 7900HT Fast
Real-Time PCR System. BORIS primers/probe sequences were as
follows: 50-CCCATTGTGCCACCATCA-30 (forward); 50-AGCATG
CAAGTTGCGCATAT-30 (reverse); 6FAM-ACGGAAAAGCGACC
TAC-MGB (BORIS probe). Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) primers/probe mixture was purchased as
Predeveloped Assay (Applied Biosystems, Foster City, CA, USA).
Levels of BORIS mRNA were expressed in relative copy numbers
normalised against the housekeeping gene GAPDH (comparative
CT method).
The chicken anti-BORIS antibody
The chicken anti-BORIS antibody was generated and characterized
as described previously (Loukinov et al, 2002). In the present
study, this antibody was further assessed for its specificity in a
series of additional assays as described in the Supplementary
Figure 1 published online.
Western blot analysis
For western blot analysis, lysates from cells were prepared
according to Klenova et al (1993) with modifications. Lysates
from breast tissues were prepared as follows. Tissue was
homogenized in the lysis buffer at the ratio 500mm
3 tissue/
100ml buffer. The buffer was composed of 20mM Tris-buffered
with HEPES pH 8.0/2mM EDTA/0.5 M NaCl/0.5% Na deoxycholate/
0.5% Triton X-100/0.25 M sucrose; 50mM 2-ME, 250mM PMSF
and 1mM pepstatin (10ml/10ml) were added to the buffer
immediately before use. The homogenate was kept on ice for
30min, filtered through gauze and centrifuged for 15min, at þ41C
and 13000r.p.m. Samples containing high concentration of lipids
were additionally precipitated with acetone. For this purpose, an
equal volume of acetone was added to the supernatant, and the
solution was mixed, kept at  201C for 1h and then centrifuged for
10min at þ41C and 13000r.p.m. The supernatant was discarded,
pellet dried at room temperature and re-suspended in SDS-
loading/lysis buffer. Western blot assay was conducted as
described previously with the anti-BORIS or anti-a-tubulin
(Sigma) antibodies (Loukinov et al, 2002). Detection was
performed with enhanced chemiluminescence reagent (Amersham
Biosciences, now GE Healthcare, Buckingham, UK) according to
the manufacturer’s instructions. Quantification of the bands was
performed by using the Image J software (http://rsb.info.nih.gov/ij/),
and values were obtained from the ratios CTCF/a-tubulin.
Immunostaining
Immunohistochemical analysis was performed by staining with
the Vectastain Elite ABC standard kit (Vector Laboratories,
Peterborough, UK) as suggested by the manufacturer. The dilution
of the chicken anti-BORIS antibody applied to the sections was
1:50 and the secondary goat biotinylated anti-chicken antibody
(Vector) was used at 1:150 dilution. The sections were then
counterstained with haematoxylin only or with haematoxylin and
eosin. The immunological staining was evaluated by using the
immunoreactivity score (IRS) as described previously (Beck et al,
1995). In brief, the percentage of CTCF-positive cells was divided
into four categories: (1) o10%, (2) 11–50%, (3) 51–80% and (4)
480%, whereas the staining intensity was given a scale from 0
(no detectable immunostaining) to 3 (strong immunostaining).
The IRS (0–12) was then calculated by multiplying the score
values. Scoring was performed in a blinded fashion by two
independent scorers, with each slide read twice; the results in the
Table 1 represent the average score for each sample. The IRS was
considered significant when the values were more than 1.
Statistical analysis
Statistical analysis was carried out using unpaired Student’s t-test.
A significant value was detected when the probability was below
the 5% confidence level (Po0.05).
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Analysis of BORIS expression in breast cell lines
We first investigated the levels of BORIS protein in a panel of breast
cancer cell lines composed of two non-malignant (HBL100 and HB4a)
and 16 malignant cell lines. Western blot analysis revealed that all cell
lines contained the 85-kDa band characteristic for BORIS (Figure 1A).
However, the levels of BORIS were different in the cell lines tested: the
lowest were observed in the cancer cell lines DU4475 and ZR-75-30;
the highest levels were detected in CAMA1 and MDA-MB-435
(Figure 1A). No BORIS was detected in primary breast cells obtained
from breast reduction (BR) tissues (Figure 1B).
We then performed immunohistochemical staining with anti-
BORIS antibody in a small panel of breast cancer cell lines to
confirm BORIS expression. Consistent with the results of the
western analysis, low levels of BORIS were detected in the
breast cancer cell line MCF-7, whereas the increased levels of
BORIS, particularly in the cytoplasm, was observed in MDA-MB-
468 and MDA-MB-435 (Figure 1C, upper panel). Although the
levels of BORIS in MDA-MB-468 were lower than in MDA-MB-435
in the western assay, they seemed higher in the immunostaining.
The explanation for this is given in the Discussion section. No
staining was detected with the secondary antibody only (Figure 1C,
lower panel). From these data, we conclude that BORIS protein is
absent in normal breast cells; however, it is present at variable
levels in all breast cancer cell lines, both in the nucleus and in
the cytoplasm, in agreement with the earlier report (Loukinov
et al, 2002).
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MDA-MB-157
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Figure 1 BORIS protein is present in breast cancer cell lines. (A) Western blot analysis of BORIS protein levels in human breast cell lines. Cellular extracts
were prepared from 5 10
6 cells and equal amounts (20mg) of total protein were loaded onto SDS–PAGE. Samples were electrophoretically separated,
blotted and probed with the anti-BORIS antibody. The membrane was re-probed with the anti-a-tubulin antibody, which served as an internal control for
protein loading. The images were quantified using the Image J software. The ratios of the intensity of the BORIS bands over the intensity of the
corresponding a-tubulin bands were determined and expressed as fold change relative to the lowest BORIS/a-tubulin ratio found in DU4475 (designated as
1.0). Numbers below each BORIS lane show these results. (B) Western blot analysis of primary breast cells compared to MCF-7 cells. Cellular extracts were
prepared from 5 10
6 cells and equal amounts (40mg) of total protein were loaded onto SDS–PAGE. Samples were electrophoretically separated, blotted
and probed with the anti-BORIS antibody. The membrane was re-probed with the anti-a-tubulin antibody, which served as an internal control for protein
loading. (C) Immunostaining of BORIS in breast cell lines with low and higher expression levels of BORIS. Cells were grown in eight-well chamber slides,
fixed with 4% formaldehyde followed by immunohistochemistry protocol as described under the Materials and Methods section. Cells immunostained with
the anti-BORIS antibody are shown in the upper panel. Panels below demonstrate background staining with haematoxylin plus secondary antibodies only.
Images were taken at  100 magnification.
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We then assessed BORIS expression in four BR tissues. The
immunohistochemical staining for BORIS was negative in all these
tissues (a typical example is shown in Figure 2A and data
presented in Table 1 and Figure 3). Next, we used paired peripheral
(PP) breast tissues obtained from the same patient with breast
tumour. We carried out immunohistochemical staining for BORIS
on 15 available PP tissues. The staining revealed that only one
sample was very weakly positive for BORIS (IRSo1). The average
IRS value for this group was 0.067±0.067. These results are
presented in Table 1 and Figure 3. We then evaluated BORIS
expression in a panel of 58 primary breast tumours, which
consisted of tumours with different phenotypes: five ductal
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Figure 2 BORIS expression in normal and tumour breast tissues. (A) BORIS expression in the BR mammoplasty tissue. Frozen BR tissue was sectioned
and immunostained with the anti-BORIS antibody as described under the Materials and Methods section. Left panel, primary and secondary antibody; right
panel, secondary antibody only. Images were taken at  10,  40 and  100 magnification. (B) BORIS expression in breast tumours with different IRS.
Frozen breast tumour tissues were sectioned and immunostained with the anti-BORIS antibody as described under the Materials and Methods section.
Images were taken at  40 (upper panel) and  100 (lower panel) magnification. DCIS¼ductal carcinoma in situ; IDC¼invasive ductal carcinoma;
IAC¼invasive adenocarcinoma. (C) Western blot analyses of BORIS in selected breast tissues with different IRS and the corresponding PP tissues. Extracts
from tissues were prepared as described under the Materials and Methods section, total protein concentration was determined for each sample and equal
amount (20mg) of total protein was loaded onto SDS–PAGE. Samples were electrophoretically separated, blotted and probed with the anti-BORIS
antibody. The same membrane was stripped and re-probed with the a-tubulin antibody (loading control). (D) Real-time RT–PCR analysis of BORIS mRNA
in selected breast tumours with different IRS paired with the corresponding peripheral tissue. Levels of BORIS mRNA were calculated using comparative Ct
method (DDCt) and normalised to GAPDH levels.
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scarcinomas in situ (DCIS), eight invasive adenocarcinomas (IAC),
33 invasive ductal carcinomas (IDC), seven invasive lobular
carcinomas (ILC), three tumours with mixed phenotypes (MIXED)
and two mucinous carcinomas (MUC CA). These results are
presented in Table 1 and Figure 3. As determined by immuno-
histochemical staining, BORIS was detected in 70.7% (41 of 58
samples), with the average IRS¼2.53±0.04 (‘all phenotype
group’).
The IRS values for BORIS in different groups were as follows:
2±0.316 in DCIS; 1.5±0.298 in IAC; 2.85±0.079 in IDC;
2.43±0.199 in ILC; 2.67±1.539 in mixed tumours and 3±0i n
mucinous carcinomas. Using an unpaired Student’s t-test, we
confirmed that the difference was significant for the following
groups: DCIS, Pp0.05; IAC, Pp0.05; IDC, Pp0.0002; ILC,
Pp0.004, and ‘all tumour’, Pp0.003. There were insufficient
numbers of samples in the mixed tumours and mucinous
carcinomas for statistical analysis.
Figure 2B represents typical examples of immunohistochemical
staining for BORIS in breast tumour tissues with different IRS.
Similarly to the breast cell lines, the distribution of BORIS is both
nuclear and cytoplasmic. The staining also reveals heterogeneity of
different tissue specimens for BORIS. Thus, different proportions
of BORIS-positive tumour cells and different degrees of BORIS
expression can be observed in the specimens (Figure 2B and
Table 1).
We also performed western analysis and real-time RT–PCR on
randomly selected tumour samples with different IRS and the
corresponding PP tissues. All PP tissues tested by western analysis
were negative for BORIS, whereas BORIS was present in all
samples except the specimen with the IRS BORIS¼0 (Figure 2C).
However, there was no correlation between the IRS values and the
intensity of the band. We also observed higher levels of BORIS
mRNA in the tumours compared with the PP tissues (Figure 2D);
no relationship between the IRS values and levels of BORIS mRNA
were found in this case. Possible explanations for the absence of
such correlations are given in the Discussion section.
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Figure 3 Comparison between BORIS levels in BR tissues, PP tissues
and tumours with different phenotypes. The data are shown as mean IRS
for BORIS with s.e. BR¼breast reduction tissues; PP¼paired peripheral
breast tissues, DCIS¼ductal carcinoma in situ; IAC¼invasive adenocarci-
noma; IDC¼invasive ductal carcinoma; ILC¼invasive lobular carcinoma;
MIXED¼tumours with mixed phenotypes; MUC CA¼mucinous carcinoma;
ALL¼all phenotype group.
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Figure 4 High levels of BORIS correlate with high levels of ER and PR. (A and B) Comparison between BORIS and ER (A) and BORIS and PR (B) levels
in breast tumours. Three groups with the following levels of BORIS were analysed: IRS¼0, IRS¼1–4 and IRS¼5–9. BORIS levels were assessed in the
entire tumour group; all phenotypes were included in the analysis. The mean IRS value for ER and PR are shown with the standard error. (C and D) BORIS
activates transcription from the promoters of the ER and PR genes in reporter gene assays. For transient transfections, 293T cells (1.5 10
5) were plated in
12-well dishes; 1mg of the reporter constructs pERLuc (C) and pPRLuc (D) containing promoters of ER and PR genes fused to the luciferase reporter gene
were then co-transfected with the increasing concentration of pCMV6-BORIS (shown on the graphs). The diagrams of the reporter constructs are
presented in the upper parts of the panels. Dark line depicts sequences derived from the promoter regions; arrows indicate the transcription start (one site
in the ER gene and two sites, A and B, in the PR gene). Numbers correspond to the distance from the transcription start site. Forty-eight hours post-
transfection cells were harvested and assayed for luciferase activity as described under the Materials and Methods section. Bars represent luciferase activity in
relative luciferase units (RLU). Each bar shows an average of three experiments performed in triplicate. Error bars indicate s.d.
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sHigh BORIS levels in breast tumours correlate with high
levels of the ER and PR
We also investigated a possible correlation between BORIS levels
in breast tumour tissues and clinical/pathological parameters:
tumour stage, tumour grade, tumour size, ER status, PR status,
HER-2 receptor status, lymph node metastasis, preoperative and
post-operative chemotherapy, menopausal state and patient’s age.
No correlation was found between BORIS levels and these
parameters with the exception of ER and PR.
To compare BORIS levels with ER and PR, we divided all
tumours into three groups according to the BORIS values: IRS¼0,
IRS¼1–4 and IRS¼5–9. The mean IRS for ER in the groups with
BORIS IRS¼0 and BORIS IRS¼1–4 did not differ (4.94±0.18 vs
4.56±0.17, respectively) (Figure 4A). Similarly, there was no
difference between these for IRS PR (3.82±0.18 vs 3.87±0.1,
respectively) (Figure 4B). However, we observed higher levels of
ER and PR (6.9±0.26 and 5.1±0.14, respectively) in the group
with higher levels of BORIS (IRS¼5–9) (Figure 4A and B).
BORIS activates promoters of the PR and ER genes in the
reporter assays in breast and non-breast cells
BORIS has features of a transcriptional regulator and therefore, we
asked whether BORIS could regulate the promoters of PR and ER
genes. To investigate this, we employed luciferase reporter gene
constructs containing the promoter regions of PR (De Vivo et al,
2002) and ER (deConinck et al, 1995) genes inserted upstream of the
luciferase reporter gene (Figure 4C and D). A series of standard co-
transfection assays were performed in human epithelial kidney cells,
293T, with these reporter constructs and a vector expressing the full-
length BORIS (pCMV6-BORIS). We found that BORIS progressively
activates both promoters in these cells (Figure 4C and D); thus,
suggesting that BORIS can be a positive regulator of transcription of
both genes. Similar results were also observed in the breast cancer
cell line, ZR-75-1 (Supplementary Figure 2). On the other hand,
there was no effect from the increasing concentrations of BORIS on
the basic reporter luciferase construct, pGL2, in both cell lines
(Supplementary Figure 3). These results corroborate our previous
observations of correlation between high BORIS levels in breast
tumours and high levels of the ER and PR (Figure 4A and B).
DISCUSSION
The aim of this study was to investigate BORIS expression in breast
cancer cells and tumours. Although the antibody used in this
investigation was previously characterized for their specificity for
BORIS (Loukinov et al, 2002), we performed additional experi-
ments to confirm these observations (Supplementary Figure 1). In
these experiments, the polyclonal chicken anti-BORIS antibody
was shown to be specific by the following criteria: (1) intensity of
the immunohistochemical staining of the breast tumour tissue
was significantly reduced after preincubation of the antibody with
the blocking peptide, (2) intensity of the immunofluorescent
staining of the cells in culture was significantly reduced after
preincubation of the antibody with the blocking peptide, (3)
western analysis of the N-terminal domain of BORIS expressed in
E. coli and the protein produced from the full-length BORIS cDNA
in the eukaryotic-expressing vector in 293T cells demonstrated
the presence of the recombinant products, recognised by the anti-
BORIS antibody and (4) preparative immunoprecipitation of the
cell lysates with the anti-BORIS antibody and subsequent analysis
of the 85-kDa band characteristic for BORIS by mass-spectrometry
(MS/MS sequencing), revealed the presence of peptides matching
BORIS in this band.
Using this antibody, we found that BORIS was expressed at
different levels in all 18 breast cancer cell lines used in the
experiments. It is, however, difficult to correlate the levels of
BORIS detected by western analysis and immunohistochemical
staining of the same cells (e.g. MDA-MB-435 and MDA-MB-468,
Figure 1A and C). Thus, the apparently denser accumulation of
staining in MDA-MB-468 cells as seen by the immunohistochem-
istry can be due to different cell morphology of MDA-MB-468
(small cytoplasm, more rounded cell shape).
As BORIS was detected in 70.7% of breast tumours, the presence
of BORIS in 100% cell lines may indicate that the selective pressure
in vivo on some tumours may be absent in vitro. The availability of
the component(s) in the growth media that may be important for
BORIS activation could be a factor; access to such component(s)
may be restricted in the microenvironment of some tumours.
Given the complex nature of BORIS regulation at the transcrip-
tional level it may be possible that different promoters are involved
in the control of BORIS expression in cultured cells and tumours;
thus, providing different molecular mechanisms of BORIS activa-
tion in vivo and in vitro (Renaud et al, 2007) (see below).
There was no obvious correlation between the amount of BORIS
in non-malignant and malignant cells, which suggests that BORIS
may not play a key role in the establishment of the malignant
phenotype. This is supported by the lack of correlation between
BORIS levels in breast tumours and lymph node metastasis, which
is used in clinical practice as an indicator of the malignant breast
cancer (Tobler and Detmar, 2006; Eccles et al, 2007). On the other
hand, BORIS was not detected in primary normal breast cells,
which suggests that BORIS is likely to be associated with the
immortalised and malignant cells.
The immunohistochemical staining revealed that the levels of
BORIS protein were significantly higher in all breast tumours
compared with normal and PP tissues; 70.7% of breast tumours
were BORIS-positive. All normal breast tissues from BR specimens
were negative for BORIS. Only 1 tissue out of 15 from the group
of the PP tissues was very weakly positive; we explain this by
influence of the tumour on normal tissue, which may take place in
some cases. Such occurrences are well documented in the literature
for mRNA/proteins for both CTA and non-CTA genes (Janz et al,
2002; Zhao et al, 2004).
In our investigation, the levels of the BORIS mRNA were
considerably higher in breast tumour tissues compared with the
PP tissues. However, no correlation was observed between the levels
of BORIS mRNA and protein (Figure 2D). Lack of coordinated
expression between mRNA and protein is not unusual – poor
correlation between expression of an mRNA and the corresponding
protein is now generally acknowledged and accepted (Abbott, 1999).
Genes showing no obvious direct link between expression of
mRNA and corresponding protein in various cell lines and tumours
are described in the literature and include p27
Kip (Ciaparrone et al,
1998), ERs and PRs (Tong et al, 1999). The heterogenous nature of
breast tumour tissues may also account for this discrepancy as
different parts of the tissues are used for extraction of protein and
mRNA. The latter may also be the reason for the lack of good
correlation between the immunohistochemical staining (IRS for
BORIS) and western analysis data (Figure 2A and C).
We noted the heterogenous pattern of BORIS staining in breast
tumour tissues, showing single BORIS-positive cells or clusters of
positive cells, with varying staining intensity. This may explain the
fact that the IRS for BORIS has not reached the values higher than
9. Such pattern of expression is common to CTA, examples include
distribution of MAGE antigens in various tumours (Jungbluth
et al, 2000a,b).
Other CTA have also been detected in breast tumours. Although
some CTA can be detected in breast tumours of different type,
other CTA are observed only in particular breast tumours. Thus,
XAGE-1 was observed in invasive lobular as well as ductal
carcinoma (Egland et al, 2002), and NY-BR-1 was detected in
various breast carcinomas (Theurillat et al, 2007). MAGE-A was
seen frequently in primary ductal breast carcinomas, but not in
lobular carcinomas (Otte et al, 2001). Almost 81% of the ductal
BORIS expression in breast tumours
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2002).
Cancer testis antigens are considered to be promising candidates
for tumour vaccines because of their immunogenicity and tissue-
restricted expression (Scanlan et al, 2004; Kalejs and Erenpreisa,
2005). Recent studies using a mouse model revealed that immune
response to BORIS can be developed in the organism; and
furthermore, such immune response has protective effects against
several mouse tumours of different origin (Loukinov et al, 2006;
Ghochikyan et al, 2007). These data indicate that BORIS may be an
attractive candidate for the development of the future cancer
vaccine. For such a therapy, it will be critical to determine the
presence of BORIS in the tumour given that a proportion of breast
tumours (29.3%) are BORIS negative.
The incidence of BORIS expression at the protein level (70.7%)
observed in the current study corresponds well to the reported
findings of BORIS mRNA expression in endometrial and uterine
tumours (77%) (Risinger et al, 2007). The fact that not all tumours
contain BORIS may reflect different pathways of evolution in
different tumours. Another possibility may be the presence in the
tissues of the alternative forms of BORIS not detected by the existing
antibodies. Indeed, recently 25 full-length and partial splice variants
of BORIS messages coding for 17 different proteins have been
cloned and submitted to the GenBank (E Pugacheva et al,m a n u -
script in preparation). Six full-length BORIS splice isoforms
(GenBank accession nos. DQ778125, DQ778124, DQ778126,
DQ778129, DQ778128 and DQ778127) and two partial BORIS cDNA
isoforms (GenBank accession nos. DQ778131 and DQ778130) do not
have the exon-1 sequence for the peptide recognised by the affinity-
purified chicken anti-BORIS antibody (Loukinov et al, 2002), which
was used in the present study for staining breast tissue sections.
Therefore, it is likely that results obtained by the immunostaining
with the chicken anti-BORIS antibody may underestimate the actual
frequency of presence of BORIS in breast cancers if splice variants
undetectable by this antibody are expressed.
In this investigation, we also assessed the clinical significance of
BORIS in breast tumours and found that high BORIS levels
correlated with high levels of PR and ER. Both oestrogen and
progesterone are important hormones in mammary development
in humans stimulating cell growth, proliferation and differentia-
tion (Barron et al, 1997; Humphreys et al, 1997; Anderson, 2002).
Moreover, both hormones have been demonstrated to promote
breast tumorigenesis (Medina, 2005; Montero Girard et al, 2007). It
is conceivable that BORIS may stimulate production of both PR
and ER, which in turn may support tumour progression. Further
experiments confirmed that BORIS could activate promoters of
both ER and PR genes in the reporter assays in cells of breast and
non-breast origin; thus, pointing at the possible molecular
mechanism of direct transcriptional regulation of these genes.
Inspection of the promoter regions of the ER and PR genes tested
in the reporter assays indeed revealed potential-binding sites for
CTCF/BORIS (Supplementary Figures 4 and 5). However, further
investigations will need to be carried out to confirm direct binding
of BORIS to these sites and clarify the role of BORIS in the
regulation of ER and PR genes.
The association of BORIS with immortalised and malignant
cells indicates that BORIS may be important in the establishment
and maintenance of cell proliferation. This may be linked to the
original BORIS function, regulation of gametogenesis, which
BORIS is likely to coordinate with other CTA family members
(Old, 2001). The appearance of common CTA (including
BORIS) during gametogenesis and tumorigenesis prompts the
hypothesis that induction of the gametogenetic programme in
somatic cells may be associated with tumour development
(Old, 2001; Kalejs and Erenpreisa, 2005). As BORIS seems to
function as an upstream regulator for several CTA (Hong et al,
2005; Vatolin et al, 2005), it is tempting to speculate that BORIS
could be the ‘master switch’ in the process of cell reprogramming,
which can guide the epigenetic machinery to a set of target genes
eventually leading to their activation. It is important to note that
BORIS may also act as an activator of genes responsible for
proliferation in particular tissues, such as ER and PR genes in
mammary glands.
An intriguing question is why and how BORIS itself is activated.
Recent reports reveal that both genetic and epigenetic mechanisms
are likely to be implicated in this process. Thus, DNA methylation,
functional p53 and CTCF play an important role in the negative
regulation of the promoters of the BORIS gene (Renaud et al,
2007). Demethylation of DNA, knockout of CTCF and absence
of functional p53 can lead to strong activation of BORIS.
Selective utilisation of different promoters (Renaud et al, 2007)
and alternative splicing (Pugacheva et al, manuscript in prepara-
tion) are also likely to contribute to regulation of BORIS
expression in different cell types. The research efforts of several
laboratories are currently focused on uncovering the details of the
molecular mechanisms of activation and regulation of BORIS.
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